Sunil Hingorani-led study breaks unique tumor defense, extends survival in mice by 70 percent; initial human studies under way
March 19, 2012
| By Dean Forbes
Pancreatic cancer tumors spread quickly and are notoriously resistant to treatment, making them among the deadliest of malignancies. Their resistance to chemotherapy stems in part from a unique biological barrier the tumor builds around itself. Now scientists at the Fred Hutchinson Cancer Research Center have found a way to break through that defense, and their research represents a potential breakthrough in the treatment of pancreatic cancer.
Medical scientist Maria Corinna Palanca-Wessels, working to defeat ovarian cancer, is among three Pacific Northwest scientists in the inaugural class of Kuni Scholars
July 11, 2011
| By Kristen Woodward
Dr. Maria Corinna Palanca-Wessels of the Fred Hutchinson Cancer Research Center is one step closer to her goal of making ovarian tumors more susceptible to chemotherapy thanks to a two-year, $200,000 award from the Wayne D. Kuni and Joan E. Kuni Foundation of Vancouver, Wash., and the Kuni family (through the 3725 Fund of the Oregon Community Foundation).
Hans-Peter Kiem and colleagues find chemo-resistant genes may enable safer, more effective treatment for brain cancer patients
May 23, 2011
| By Dean Forbes
Chemotherapy kills cancer cells, but its toxic effects on normal cells such as bone marrow and blood cells limits its use. Fred Hutchinson Cancer Research Center researchers have found a possible approach to reduce this toxicity: modify the bone marrow cells with a gene that makes them resistant to chemotherapy.
Sunil Hingorani and an international team of investigators shed light on reasons patients are often resistant to gemcitabine treatment
May 25, 2009
An international team of investigators, led by Cancer Research UK scientists and including the Fred Hutchinson Cancer Research Center's Dr. Sunil Hingorani, have discovered a mechanism that may explain why pancreas-cancer patients are often resistant to a common chemotherapy treatment called gemcitabine.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.